Kyverna Therapeutics (KYTX) Earnings Date, Estimates & Call Transcripts $4.12 +0.04 (+0.98%) (As of 11/20/2024 ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Kyverna Therapeutics Latest Earnings SummaryLatest Earnings DateNov. 13EstimatedActual EPS (Nov. 13) -$0.80 Beat By $0.01 Consensus EPS (Nov. 13) -$0.81 Kyverna Therapeutics issued Q3 2024 earnings on November 13, 2024, reporting an EPS of -$0.80, which topped the consensus estimate of -$0.81 by $0.01. Quarterly revenue was reported to be $0.01 million. With a trailing EPS of $0.00, Kyverna Therapeutics' earnings are expected to decrease next year, from ($3.31) to ($3.98) per share. Get Kyverna Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kyverna Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataKYTX Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.KYTX Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Crypto 101 MediaTop "Sleeping Giant" Crypto In The Market NowTop "Sleeping Giant" Crypto In The Market Now We're looking at potential returns that could rewrite your financial future. Click here to discover our #1 crypto pick before it's too late Kyverna Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20241-$1.20-$1.20-$1.20Q2 20241-$0.69-$0.69-$0.69Q3 20242-$0.83-$0.68-$0.76Q4 20242-$0.87-$0.70-$0.79FY 20246-$3.59-$3.27-$3.43Q1 20251-$0.72-$0.72-$0.72Q2 20251-$0.74-$0.74-$0.74Q3 20251-$0.76-$0.76-$0.76Q4 20251-$0.78-$0.78-$0.78FY 20254($3.00)($3.00)($3.00) Kyverna Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks11/13/2024--$0.81-$0.80+$0.01--$0.01M8/12/2024Q2 2024-$0.70-$0.67+$0.03-$0.67$3.75M-5/14/2024Q1 2024-$0.84-$1.12 -$0.28-$1.12$3.75M- Kyverna Therapeutics Earnings - Frequently Asked Questions When did Kyverna Therapeutics announce their last quarterly earnings? Kyverna Therapeutics (NASDAQ:KYTX) last announced its quarterly earning data on Wednesday, November 13, 2024. Learn more on KYTX's earnings history. Did Kyverna Therapeutics beat their earnings estimates last quarter? In the previous quarter, Kyverna Therapeutics (NASDAQ:KYTX) reported ($0.80) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.81) by $0.01. Learn more on analysts' earnings estimate vs. KYTX's actual earnings. How much revenue does Kyverna Therapeutics generate each year? Kyverna Therapeutics (NASDAQ:KYTX) has a recorded annual revenue of $7.03 million. How much profit does Kyverna Therapeutics generate each year? Kyverna Therapeutics (NASDAQ:KYTX) has a recorded net income of -$60.37 million. KYTX has generated $0.00 earnings per share over the last four quarters. What is Kyverna Therapeutics's EPS forecast for next year? Kyverna Therapeutics's earnings are expected to decrease from ($3.31) per share to ($3.98) per share in the next year. ` More Earnings Resources from MarketBeat Related Companies Entrada Therapeutics Earnings Date Arbutus Biopharma Earnings Date CorMedix Earnings Date Tectonic Therapeutic Earnings Date Phathom Pharmaceuticals Earnings Date Exscientia Earnings Date ORIC Pharmaceuticals Earnings Date AnaptysBio Earnings Date Stoke Therapeutics Earnings Date Dianthus Therapeutics Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Alibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of EarningsLam Research Proves Analysts Wrong with a Strong Earnings Report Top "Sleeping Giant" Crypto In The Market Now (Ad)Top "Sleeping Giant" Crypto In The Market Now We're looking at potential returns that could rewrite your financial future. Click here to discover our #1 crypto pick before it's too late This page (NASDAQ:KYTX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kyverna Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kyverna Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
